You just read:

MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections

News provided by

MGB Biopharma

02 Jun, 2015, 09:00 BST